CONFERENCES

      Institute for In Vitro Sciences Workshops

      The Institute for In Vitro Sciences (IIVS) is a research laboratory dedicated to the advancement of high quality in vitro testing methods worldwide.

      In Vitro Models for Testing Oral Tobacco and Nicotine Products 2024

      Date

      Jan 24, 2024 - Jan 26, 2024

      Location

      Online

      The 9th workshop in IIVS's In Vitro Workshop series focuses on assessing oral use products, addressing the unique scientific and modeling needs associated with these products. Dedicated to the memory of Dr. Martha Moore, a renowned genetic toxicology expert, the workshop explores the adaptation of standard in vitro assays, such as the Ames test and micronucleus assay, for oral products.

      See related presentations

      In Vitro Exposure Systems and Dosimetry Assessment Tools for Inhaled Tobacco Products 2016

      Date

      Apr 04, 2016 - Apr 06, 2016

      Location

      Bethesda, USA

      This workshop provides attendees with a deeper understanding of the issues involving exposure and dosimetry of aerosols to cells and tissues in culture.

      See related presentations

      Assessment of in vitro COPD models for tobacco regulatory science 2014

      Date

      Dec 08, 2014 - Dec 10, 2014

      Location

      Bethesda, USA

      This workshop brings together stakeholders representing regulatory agencies, academia, industry and animal protection, to address the research priorities articulated by the Family Smoking Prevention and Tobacco Control Act of 2009 established the Food and Drug Administration Center for Tobacco Products (FDA-CTP).

      See related presentations

      PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
      ​
      Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.